Heparan sulfate: a stem cell therapy target?
In this issue of Blood, Saez et al demonstrate that inhibition of heparan sulfate proteoglycan production by bone marrow osteolineage stromal cells results in hematopoietic stem cell egress from the bone marrow niche into the peripheral circulation.
CHILDREN'S HOSPITAL OF PHILADELPHIA; UNIVERSITY OF PENNSYLVANIA.
Timothy S
TS
Olson
D000818:Animals; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006497:Heparan Sulfate / Q000096:biosynthesis*; D008297:Male; D017351:N-Acetylglucosaminyltransferases / Q000378:metabolism*; D017154:Stromal Cells / Q000378:metabolism*; D019172:Transplantation Conditioning; D000099058:Exostosin 1
D006497:Heparan Sulfate; D017351:N-Acetylglucosaminyltransferases; D000099058:Exostosin 1